1. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (10th December 2020) Authors: Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (9th November 2020) Authors: Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗